|
ATE318832T1
(de)
|
1990-06-11 |
2006-03-15 |
Gilead Sciences Inc |
Verfahren zur vervendung von nukleinsäureliganden
|
|
ES2188985T3
(es)
|
1996-08-30 |
2003-07-01 |
Jens Peter Furste |
Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos.
|
|
US5989912A
(en)
|
1996-11-21 |
1999-11-23 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
|
ATE492644T1
(de)
|
1999-09-09 |
2011-01-15 |
Curevac Gmbh |
Transfer von mrna unter verwendung von polykationischen verbindungen
|
|
ATE291925T1
(de)
|
2001-06-05 |
2005-04-15 |
Curevac Gmbh |
Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
|
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
|
US7074596B2
(en)
|
2002-03-25 |
2006-07-11 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthesis and use of anti-reverse mRNA cap analogues
|
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
|
DE10335833A1
(de)
|
2003-08-05 |
2005-03-03 |
Curevac Gmbh |
Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
|
|
DE102004042546A1
(de)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Kombinationstherapie zur Immunstimulation
|
|
DE102005023170A1
(de)
|
2005-05-19 |
2006-11-23 |
Curevac Gmbh |
Optimierte Formulierung für mRNA
|
|
EP2049665A2
(en)
|
2006-07-28 |
2009-04-22 |
Applera Corporation |
Dinucleotide mrna cap analogs
|
|
JP2010507361A
(ja)
|
2006-07-31 |
2010-03-11 |
キュアバック ゲーエムベーハー |
具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
|
|
DE102006035618A1
(de)
|
2006-07-31 |
2008-02-07 |
Curevac Gmbh |
Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
|
|
DE102006061015A1
(de)
|
2006-12-22 |
2008-06-26 |
Curevac Gmbh |
Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
US8153773B2
(en)
|
2007-06-19 |
2012-04-10 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap
|
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
|
WO2009046738A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
|
|
WO2009046739A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating prostate cancer (pca)
|
|
EP3100718B1
(en)
|
2008-01-02 |
2019-11-27 |
Arbutus Biopharma Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
|
JP5721441B2
(ja)
|
2008-01-31 |
2015-05-20 |
キュアバック ゲーエムベーハーＣｕｒｅｖａｃ Ｇｍｂｈ |
免疫賦活剤／アジュバントとしての式（Ｉ）（ＮｕＧｌＸｍＧｎＮｖ）ａで表される核酸分子及びその誘導体
|
|
EP2279254B1
(en)
|
2008-04-15 |
2017-07-05 |
Protiva Biotherapeutics Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
PL215513B1
(pl)
|
2008-06-06 |
2013-12-31 |
Univ Warszawski |
Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
|
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
|
AU2009303345B2
(en)
|
2008-10-09 |
2015-08-20 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
WO2010048536A2
(en)
|
2008-10-23 |
2010-04-29 |
Alnylam Pharmaceuticals, Inc. |
Processes for preparing lipids
|
|
EP3699172A3
(en)
|
2008-11-10 |
2020-11-18 |
Arbutus Biopharma Corporation |
Novel lipids and compositions for the delivery of therapeutics
|
|
EP2391343B1
(en)
|
2009-01-29 |
2017-03-01 |
Arbutus Biopharma Corporation |
Improved lipid formulation for the delivery of nucleic acids
|
|
CA3042927C
(en)
|
2009-05-05 |
2022-05-17 |
Arbutus Biopharma Corporation |
Lipid compositions for the delivery of therapeutic agents
|
|
KR20220038506A
(ko)
|
2009-06-10 |
2022-03-28 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
|
EP2281579A1
(en)
|
2009-08-05 |
2011-02-09 |
BioNTech AG |
Vaccine composition comprising 5'-Cap modified RNA
|
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
|
EP4481047A3
(en)
|
2010-06-03 |
2025-04-16 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
EP2449113B8
(en)
|
2010-07-30 |
2015-11-25 |
CureVac AG |
Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
|
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
|
WO2012113413A1
(en)
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
WO2013059475A1
(en)
|
2011-10-18 |
2013-04-25 |
Life Technologies Corporation |
Alkynyl-derivatized cap analogs, preparation and uses thereof
|
|
US9512073B2
(en)
|
2011-10-27 |
2016-12-06 |
Massachusetts Institute Of Technology |
Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
|
|
WO2013073480A1
(ja)
|
2011-11-18 |
2013-05-23 |
日油株式会社 |
細胞内動態を改善したカチオン性脂質
|
|
EP2623121A1
(en)
|
2012-01-31 |
2013-08-07 |
Bayer Innovation GmbH |
Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
|
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
|
WO2013120500A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
|
ES2660129T3
(es)
|
2012-03-27 |
2018-03-20 |
Curevac Ag |
Moléculas de ácido nucleico artificiales que comprenden un 5'UTR-TOP
|
|
WO2013143698A1
(en)
|
2012-03-27 |
2013-10-03 |
Curevac Gmbh |
Artificial nucleic acid molecules
|
|
RU2658490C2
(ru)
|
2012-03-27 |
2018-06-21 |
Кьюрвак Аг |
Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
|
|
EP2854857B1
(en)
|
2012-05-25 |
2018-11-28 |
CureVac AG |
Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
|
|
SG11201506052PA
(en)
|
2013-02-22 |
2015-09-29 |
Curevac Gmbh |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
AU2014310935B2
(en)
|
2013-08-21 |
2019-11-21 |
CureVac SE |
Combination vaccine
|
|
CN105517569A
(zh)
|
2013-08-21 |
2016-04-20 |
库瑞瓦格股份公司 |
狂犬病疫苗
|
|
AU2014310932B2
(en)
|
2013-08-21 |
2019-06-06 |
CureVac SE |
Composition and vaccine for treating lung cancer
|
|
BR112016000889A2
(pt)
|
2013-08-21 |
2017-12-12 |
Curevac Ag |
composição e vacina para tratamento de câncer de próstata
|
|
SG10201801428RA
(en)
|
2013-08-21 |
2018-03-28 |
Curevac Ag |
Method for increasing expression of rna-encoded proteins
|
|
BR112016003361A2
(pt)
|
2013-08-21 |
2017-11-21 |
Curevac Ag |
vacina do vírus sincicial respiratório (rsv)
|
|
WO2015062738A1
(en)
|
2013-11-01 |
2015-05-07 |
Curevac Gmbh |
Modified rna with decreased immunostimulatory properties
|
|
CA2927254C
(en)
|
2013-12-30 |
2023-10-24 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
SG11201604198YA
(en)
|
2013-12-30 |
2016-07-28 |
Curevac Ag |
Methods for rna analysis
|
|
AU2014375402B2
(en)
|
2013-12-30 |
2020-10-01 |
CureVac SE |
Artificial nucleic acid molecules
|
|
CA2935878C
(en)
|
2014-03-12 |
2023-05-02 |
Curevac Ag |
Combination of vaccination and ox40 agonists
|
|
WO2015149944A2
(en)
|
2014-04-01 |
2015-10-08 |
Curevac Gmbh |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
|
SG11201608605QA
(en)
|
2014-06-10 |
2016-12-29 |
Curevac Ag |
Methods and means for enhancing rna production
|
|
KR102559979B1
(ko)
|
2014-06-24 |
2023-07-25 |
샤이어 휴먼 지네틱 테라피즈 인크. |
핵산의 전달용 입체화학적으로 풍부한 조성물
|
|
CA2969619A1
(en)
|
2014-12-03 |
2016-06-09 |
Agilent Technologies, Inc. |
Guide rna with chemical modifications
|
|
EP4023755B1
(en)
|
2014-12-12 |
2023-04-26 |
CureVac SE |
Artificial nucleic acid molecules for improved protein expression
|
|
CA2962849A1
(en)
|
2014-12-16 |
2016-06-23 |
Curevac Ag |
Ebolavirus and marburgvirus vaccines
|
|
BR112017009835A2
(pt)
|
2014-12-30 |
2017-12-26 |
Curevac Ag |
moléculas de ácido nucleico artificiais
|
|
WO2016118724A1
(en)
|
2015-01-21 |
2016-07-28 |
Moderna Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
EP3247398A4
(en)
|
2015-01-23 |
2018-09-26 |
Moderna Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
JP6640750B2
(ja)
*
|
2015-01-30 |
2020-02-05 |
日油株式会社 |
カチオン性脂質
|
|
EP4353257A3
(en)
|
2015-04-13 |
2024-08-07 |
CureVac Manufacturing GmbH |
Method for producing rna compositions
|
|
US10780054B2
(en)
|
2015-04-17 |
2020-09-22 |
Curevac Real Estate Gmbh |
Lyophilization of RNA
|
|
AU2016251687C1
(en)
|
2015-04-22 |
2023-07-27 |
CureVac SE |
RNA containing composition for treatment of tumor diseases
|
|
WO2016176330A1
(en)
|
2015-04-27 |
2016-11-03 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
WO2016174271A1
(en)
|
2015-04-30 |
2016-11-03 |
Curevac Ag |
Immobilized poly(n)polymerase
|
|
EP3289077B1
(en)
|
2015-04-30 |
2020-04-15 |
CureVac AG |
Method for in vitro transcription using an immobilized restriction enzyme
|
|
WO2016180430A1
(en)
|
2015-05-08 |
2016-11-17 |
Curevac Ag |
Method for producing rna
|
|
DK3294326T3
(da)
|
2015-05-15 |
2021-05-31 |
Curevac Ag |
Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion
|
|
WO2016184575A1
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
|
CN107530448A
(zh)
|
2015-05-20 |
2018-01-02 |
库瑞瓦格股份公司 |
包含长链rna的干粉组合物
|
|
EP4098743A1
(en)
|
2015-05-29 |
2022-12-07 |
CureVac AG |
Method for adding cap structures to rna using immobilized enzymes
|
|
DK3303583T3
(da)
|
2015-05-29 |
2020-07-13 |
Curevac Real Estate Gmbh |
Fremgangsmåde til fremstilling og oprensning af rna, omfattende mindst et trin til tangential-flow-filtrering
|
|
EP3310384A1
(en)
|
2015-06-17 |
2018-04-25 |
CureVac AG |
Vaccine composition
|
|
EP4239080A3
(en)
|
2015-07-01 |
2023-11-01 |
CureVac Manufacturing GmbH |
Method for analysis of an rna molecule
|
|
US10501768B2
(en)
|
2015-07-13 |
2019-12-10 |
Curevac Ag |
Method of producing RNA from circular DNA and corresponding template DNA
|
|
WO2017021546A1
(en)
|
2015-08-05 |
2017-02-09 |
Curevac Ag |
Epidermal mrna vaccine
|
|
EP3699288A1
(en)
|
2015-08-07 |
2020-08-26 |
CureVac AG |
Process for the in vivo production of rna in a host cell
|
|
WO2017025447A1
(en)
|
2015-08-10 |
2017-02-16 |
Curevac Ag |
Method of increasing the replication of a circular dna molecule
|
|
US12258567B2
(en)
|
2015-08-28 |
2025-03-25 |
CureVac SE |
Artificial nucleic acid molecules
|
|
US20190054112A1
(en)
|
2015-09-18 |
2019-02-21 |
Moderna Therapeutics, Inc. |
Polynucleotide formulations for use in the treatment of renal diseases
|
|
DK4276189T3
(da)
|
2015-09-21 |
2026-05-26 |
Trilink Biotechnologies Llc |
Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe
|
|
US11395798B2
(en)
*
|
2015-10-08 |
2022-07-26 |
Nof Corporation |
O/W type emulsion
|
|
WO2017064146A1
(en)
|
2015-10-12 |
2017-04-20 |
Curevac Ag |
Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
|
|
WO2017066782A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Hydrophobic mrna cap analogs
|
|
US11866754B2
(en)
|
2015-10-16 |
2024-01-09 |
Modernatx, Inc. |
Trinucleotide mRNA cap analogs
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
JP2018530587A
(ja)
|
2015-10-16 |
2018-10-18 |
モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． |
ｍＲＮＡキャップ類似体およびｍＲＮＡキャッピングの方法
|
|
WO2017066791A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Sugar substituted mrna cap analogs
|
|
DK3362461T3
(da)
|
2015-10-16 |
2022-05-09 |
Modernatx Inc |
Mrna-cap-analoger med modificeret phosphatbinding
|
|
MA46023A
(fr)
|
2015-10-22 |
2019-07-03 |
Modernatx Inc |
Vaccin contre le virus de la grippe à large spectre
|
|
EP3364981A4
(en)
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
WO2018081480A1
(en)
|
2016-10-26 |
2018-05-03 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
WO2017081110A1
(en)
|
2015-11-09 |
2017-05-18 |
Curevac Ag |
Rotavirus vaccines
|
|
EP3374504B1
(en)
|
2015-11-09 |
2025-03-19 |
CureVac SE |
Optimized nucleic acid molecules
|
|
DK3386484T3
(da)
|
2015-12-10 |
2022-07-04 |
Modernatx Inc |
Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
|
|
WO2017108087A1
(en)
|
2015-12-21 |
2017-06-29 |
Curevac Ag |
Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay
|
|
WO2017109134A1
(en)
|
2015-12-22 |
2017-06-29 |
Curevac Ag |
Method for producing rna molecule compositions
|
|
RS63051B1
(sr)
|
2015-12-22 |
2022-04-29 |
Modernatx Inc |
Jedinjenja i kompozicije za intracelularnu isporuku agenasa
|
|
EP3394280A1
(en)
|
2015-12-23 |
2018-10-31 |
CureVac AG |
Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
|
US12612654B2
(en)
|
2016-02-12 |
2026-04-28 |
CureVac SE |
Method for analyzing RNA
|
|
US20190049414A1
(en)
|
2016-02-15 |
2019-02-14 |
Curevac Ag |
Method for analyzing by-products of rna in vitro transcription
|
|
WO2017140905A1
(en)
|
2016-02-17 |
2017-08-24 |
Curevac Ag |
Zika virus vaccine
|
|
EP3423595A1
(en)
|
2016-03-03 |
2019-01-09 |
CureVac AG |
Rna analysis by total hydrolysis
|
|
WO2017162297A1
(en)
|
2016-03-24 |
2017-09-28 |
Curevac Ag |
Immobilized inorganic pyrophosphatase (ppase)
|
|
EP4487869A3
(en)
|
2016-04-22 |
2025-07-30 |
CureVac SE |
Rna encoding a tumor antigen
|
|
US11596699B2
(en)
|
2016-04-29 |
2023-03-07 |
CureVac SE |
RNA encoding an antibody
|
|
US20180126003A1
(en)
|
2016-05-04 |
2018-05-10 |
Curevac Ag |
New targets for rna therapeutics
|
|
EP4631970A3
(en)
|
2016-05-04 |
2026-01-07 |
CureVac SE |
Nucleic acid molecules and uses thereof
|
|
WO2017191274A2
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Rna encoding a therapeutic protein
|
|
EP4233898A3
(en)
|
2016-05-04 |
2023-11-01 |
CureVac SE |
Influenza mrna vaccines
|
|
WO2017203008A1
(en)
|
2016-05-25 |
2017-11-30 |
Curevac Ag |
Novel biomarkers
|
|
WO2017212007A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Cationic carriers for nucleic acid delivery
|
|
EP3468612A1
(en)
|
2016-06-09 |
2019-04-17 |
CureVac AG |
Hybrid carriers for nucleic acid cargo
|
|
WO2017212009A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
|
US20190336611A1
(en)
|
2016-06-09 |
2019-11-07 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
|
CN109715205A
(zh)
|
2016-08-19 |
2019-05-03 |
库瑞瓦格股份公司 |
用于癌症治疗的rna
|
|
US10487105B2
(en)
|
2016-10-19 |
2019-11-26 |
Arcturus Therapeutics, Inc. |
Trinucleotide MRNA cap analogs
|
|
KR20190093816A
(ko)
|
2016-10-26 |
2019-08-26 |
큐어백 아게 |
지질 나노입자 mRNA 백신
|
|
WO2018096179A1
(en)
|
2016-11-28 |
2018-05-31 |
Curevac Ag |
Method for purifying rna
|
|
WO2018104538A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rna for treatment or prophylaxis of a liver disease
|
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
|
WO2018115525A1
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Lassa virus vaccine
|
|
WO2018115527A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Mers coronavirus vaccine
|
|
WO2018115507A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Henipavirus vaccine
|
|
WO2018126084A1
(en)
|
2016-12-30 |
2018-07-05 |
Phaserx, Inc. |
Branched peg molecules and related compositions and methods
|
|
CA3050614A1
(en)
|
2017-03-17 |
2018-09-20 |
Curevac Ag |
Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
|
|
MX2019011215A
(es)
|
2017-03-24 |
2020-02-12 |
Curevac Ag |
Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
|
|
EP3625363A1
(en)
|
2017-05-17 |
2020-03-25 |
CureVac Real Estate GmbH |
Method for determining at least one quality parameter of an rna sample
|
|
US11015204B2
(en)
|
2017-05-31 |
2021-05-25 |
Arcturus Therapeutics, Inc. |
Synthesis and structure of high potency RNA therapeutics
|
|
WO2018237369A2
(en)
|
2017-06-23 |
2018-12-27 |
Vical Incorporated |
Lipid nanoparticle (lnp)-mediated delivery of a crispr-expressing plasmid dna for treating chronic hepatitis b virus infection
|
|
JP7722629B2
(ja)
|
2017-07-04 |
2025-08-13 |
キュアバック エスイー |
新規核酸分子
|
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
|
BR112020004351A2
(pt)
|
2017-10-19 |
2020-09-08 |
Curevac Ag |
moléculas de ácido nucleico artificial
|
|
SG11202003247RA
(en)
|
2017-11-08 |
2020-05-28 |
Curevac Ag |
Rna sequence adaptation
|
|
US11931406B2
(en)
|
2017-12-13 |
2024-03-19 |
CureVac SE |
Flavivirus vaccine
|
|
CN111511928A
(zh)
|
2017-12-21 |
2020-08-07 |
库瑞瓦格股份公司 |
偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法
|
|
CN111971066B
(zh)
*
|
2018-01-18 |
2025-03-11 |
伊泽阿恩埃免疫疗法股份有限公司 |
脂质纳米颗粒
|
|
CA3094057C
(en)
*
|
2018-03-27 |
2025-04-08 |
Nof Corporation |
CATIONIC LIPID WITH IMPROVED INTRACELLULAR DYNAMICS
|
|
EP3773702A2
(en)
|
2018-04-05 |
2021-02-17 |
CureVac AG |
Novel yellow fever nucleic acid molecules for vaccination
|
|
CA3091558A1
(en)
|
2018-04-17 |
2019-10-24 |
Curevac Ag |
Novel rsv rna molecules and compositions for vaccination
|
|
US12076439B2
(en)
|
2018-05-24 |
2024-09-03 |
Translate Bio, Inc. |
Thioester cationic lipids
|
|
US20210260178A1
(en)
|
2018-06-27 |
2021-08-26 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
|
CA3102135A1
(en)
|
2018-06-28 |
2020-01-02 |
Curevac Ag |
Bioreactor for rna in vitro transcription
|
|
CA3118142A1
(en)
|
2018-11-02 |
2020-05-07 |
Genevant Sciences Gmbh |
Therapeutic methods
|
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
|
AU2019410737A1
(en)
|
2018-12-21 |
2021-06-10 |
CureVac SE |
RNA for malaria vaccines
|
|
CA3122645A1
(en)
|
2018-12-21 |
2020-06-25 |
Curevac Ag |
Methods for rna analysis
|
|
EP3920950A1
(en)
|
2019-02-08 |
2021-12-15 |
CureVac AG |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
|
WO2020219941A1
(en)
|
2019-04-26 |
2020-10-29 |
Genevant Sciences Gmbh |
Lipid nanoparticles
|
|
EP3986452A1
(en)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus mrna vaccine
|
|
WO2021028439A1
(en)
|
2019-08-14 |
2021-02-18 |
Curevac Ag |
Rna combinations and compositions with decreased immunostimulatory properties
|
|
CA3162019A1
(en)
|
2019-12-20 |
2021-06-24 |
Gemma NAVARRO |
Lipid nanoparticles for delivery of nucleic acids
|
|
US11241493B2
(en)
|
2020-02-04 |
2022-02-08 |
Curevac Ag |
Coronavirus vaccine
|
|
WO2021239880A1
(en)
|
2020-05-29 |
2021-12-02 |
Curevac Ag |
Nucleic acid based combination vaccines
|
|
US20240288407A1
(en)
|
2020-06-15 |
2024-08-29 |
CureVac SE |
Analysis of nucleic acid mixtures
|
|
EP4172194A1
(en)
|
2020-07-31 |
2023-05-03 |
CureVac SE |
Nucleic acid encoded antibody mixtures
|